Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs
- DOI
- 10.1080/14737140.2026.2640238
- Published
- 2026-03-04
- Container
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/14737140.2026.2640238,
title = {Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs},
author = {Amer M. Zeidan and Sofia Aakko and Maximilian Stahl and Jan P. Bewersdorf and Petri Bono and Teppo Huttunen and Juho Jalkanen and Elina Louramo and Aneel Nimba and Joab Williamson},
year = {2026},
journal = {Expert Review of Anticancer Therapy},
doi = {10.1080/14737140.2026.2640238},
url = {https://doi.org/10.1080/14737140.2026.2640238}
}RIS
TY - JOUR TI - Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs AU - Amer M. Zeidan AU - Sofia Aakko AU - Maximilian Stahl AU - Jan P. Bewersdorf AU - Petri Bono AU - Teppo Huttunen AU - Juho Jalkanen AU - Elina Louramo AU - Aneel Nimba AU - Joab Williamson PY - 2026 JO - Expert Review of Anticancer Therapy DO - 10.1080/14737140.2026.2640238 UR - https://doi.org/10.1080/14737140.2026.2640238 ER -
APA
Zeidan, A. M., Aakko, S., Stahl, M., Bewersdorf, J. P., Bono, P., Huttunen, T., Jalkanen, J., Louramo, E., Nimba, A., & Williamson, J. (2026). Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs. Expert Review of Anticancer Therapy. https://doi.org/10.1080/14737140.2026.2640238
Source records
- crossref · retrieved 2026-09-27T03:17:58.327Z